南非开普敦 HIV 相关结核病患者开始抗逆转录病毒治疗的时间。
Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa.
机构信息
The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
出版信息
J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):136-40. doi: 10.1097/QAI.0b013e3182199ee9.
Abstract
We studied the time interval between starting tuberculosis treatment and commencing antiretroviral treatment (ART) in HIV-infected patients (n = 1433; median CD4 count 71 cells per microliter, interquartile range: 32-132) attending 3 South African township ART services between 2002 and 2008. The overall median delay was 2.66 months (interquartile range: 1.58-4.17). In adjusted analyses, delays varied between treatment sites but were shorter for patients with lower CD4 counts and those treated in more recent calendar years. During the most recent period (2007-2008), 4.7%, 19.7%, and 51.1% of patients started ART within 2, 4, and 8 weeks of tuberculosis treatment, respectively. Operational barriers must be tackled to permit further acceleration of ART initiation as recommended by 2010 WHO ART guidelines.
摘要
我们研究了感染 HIV 的患者（n = 1433；CD4 计数中位数为每微升 71 个细胞，四分位间距：32-132）开始结核病治疗和开始抗逆转录病毒治疗（ART）之间的时间间隔，这些患者在 2002 年至 2008 年间在南非 3 个乡镇的 ART 服务机构就诊。总体中位数延迟为 2.66 个月（四分位间距：1.58-4.17）。在调整分析中，延迟在治疗地点之间有所不同，但 CD4 计数较低的患者和最近几年接受治疗的患者的延迟较短。在最近的时期（2007-2008 年），分别有 4.7%、19.7%和 51.1%的患者在结核病治疗后 2、4 和 8 周内开始接受 ART。为了允许按照 2010 年世卫组织 ART 指南的建议进一步加速开始接受 ART，必须解决业务障碍。
相似文献
1
Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa.
J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):136-40. doi: 10.1097/QAI.0b013e3182199ee9.
2
Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township.
BMC Infect Dis. 2011 Sep 30;11:258. doi: 10.1186/1471-2334-11-258.
3
Impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009-2011).
J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):487-94. doi: 10.1097/QAI.0000000000000201.
4
HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town.
BMC Infect Dis. 2018 Jul 31;18(1):356. doi: 10.1186/s12879-018-3256-9.
5
Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa.
J Acquir Immune Defic Syndr. 2013 May 1;63(1):142-5. doi: 10.1097/QAI.0b013e318288b39d.
6
Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study.
HIV Med. 2015 Apr;16(4):219-29. doi: 10.1111/hiv.12201. Epub 2014 Dec 18.
7
HIV-related symptoms and management in HIV and antiretroviral therapy patients in KwaZulu-Natal, South Africa: a longitudinal study.
SAHARA J. 2013;10(2):96-104. doi: 10.1080/17290376.2013.870119.
8
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.
AIDS. 2007 Jan 30;21(3):335-41. doi: 10.1097/QAD.0b013e328011efac.
9
Optimum time to start antiretroviral therapy in patients with HIV-associated tuberculosis: before or after tuberculosis diagnosis?
AIDS. 2011 Apr 24;25(7):1003-6. doi: 10.1097/QAD.0b013e328345ee32.
10
Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
HIV Med. 2014 Feb;15(2):77-85. doi: 10.1111/hiv.12073. Epub 2013 Aug 28.
引用本文的文献
1
Factors that shape the integration of HIV and TB services in Zomba District, Malawi.
BMC Health Serv Res. 2025 Feb 6;25(1):213. doi: 10.1186/s12913-025-12367-8.
2
New insight in molecular detection of Mycobacterium tuberculosis.
AMB Express. 2024 Jun 21;14(1):74. doi: 10.1186/s13568-024-01730-3.
3
Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low- and middle-income countries.
J Int AIDS Soc. 2019 Dec;22(12):e25423. doi: 10.1002/jia2.25423.
4
Hypertension control in integrated HIV and chronic disease clinics in Uganda in the SEARCH study.
BMC Public Health. 2019 May 6;19(1):511. doi: 10.1186/s12889-019-6838-6.
5
Treating loss-to-follow-up as a missing data problem: a case study using a longitudinal cohort of HIV-infected patients in Haiti.
BMC Public Health. 2018 Nov 19;18(1):1269. doi: 10.1186/s12889-018-6115-0.
6
Improving management of tuberculosis in people living with HIV in South Africa through integration of HIV and tuberculosis services: a proof of concept study.
BMC Health Serv Res. 2018 Sep 14;18(1):711. doi: 10.1186/s12913-018-3524-9.
7
Task-shifting point-of-care CD4+ testing to lay health workers in HIV care and treatment services in Namibia.
Afr J Lab Med. 2017 Sep 18;6(1):643. doi: 10.4102/ajlm.v6i1.643. eCollection 2017.
8
Integrating Human Immunodeficiency Virus and Reproductive, Maternal and Child, and Tuberculosis Health Services Within National Health Systems.
Curr HIV/AIDS Rep. 2016 Jun;13(3):170-6. doi: 10.1007/s11904-016-0316-x.
9
Integrating tuberculosis and HIV services in rural Kenya: uptake and outcomes.
Public Health Action. 2015 Mar 21;5(1):36-44. doi: 10.5588/pha.14.0092.
10
The Impact of Implementation Fidelity on Mortality Under a CD4-Stratified Timing Strategy for Antiretroviral Therapy in Patients With Tuberculosis.
Am J Epidemiol. 2015 May 1;181(9):714-22. doi: 10.1093/aje/kwu338. Epub 2015 Mar 18.
本文引用的文献
1
Provider-initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral treatment.
S Afr Med J. 2011 Apr;101(4):258-62. doi: 10.7196/samj.4392.
2
Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections.
Curr Opin Infect Dis. 2011 Feb;24(1):34-42. doi: 10.1097/QCO.0b013e3283420f76.
3
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa.
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):e1-8. doi: 10.1097/QAI.0b013e3181ff0bdc.
4
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa.
Clin Infect Dis. 2010 Oct 1;51(7):823-9. doi: 10.1086/656282.
5
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
AIDS. 2010 Aug 24;24(13):2041-50. doi: 10.1097/QAD.0b013e32833c703e.
6
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial.
Lancet. 2010 Jul 3;376(9734):33-40. doi: 10.1016/S0140-6736(10)60894-X.
7
Timing of initiation of antiretroviral drugs during tuberculosis therapy.
N Engl J Med. 2010 Feb 25;362(8):697-706. doi: 10.1056/NEJMoa0905848.
8
Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease.
AIDS. 2009 Sep 10;23(14):1875-80. doi: 10.1097/qad.0b013e32832e05c8.
9
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.
AIDS. 2010 Feb 20;24(4):563-72. doi: 10.1097/QAD.0b013e328333bfb7.
10
Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.
Clin Chest Med. 2009 Dec;30(4):685-99, viii. doi: 10.1016/j.ccm.2009.08.010.
Zotero 插件